Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Danil V MakarovRobert W Veltri

Abstract

We assessed the association of quantitative clinical and pathologic information, including serum and tissue pro-prostate-specific antigen (proPSA) measurements, with outcomes among men with prostate cancer in an expectant management (active surveillance) program. We identified 71 men enrolled in expectant management with frozen serum and tissue available from diagnosis: 39 subsequently developed unfavorable biopsies (Gleason score > or =7, > or =3 cores positive for cancer, >50% of any core involved with cancer), whereas 32 maintained favorable biopsies (median follow-up, 3.93 years). Serum total PSA, free PSA (fPSA), and [-2]proPSA were measured by the Beckman Coulter immunoassay. [-5/-7]proPSA was evaluated in cancer and benign-adjacent areas (BAA) by quantitative immunohistochemistry. Cox proportional hazards and Kaplan-Meier analyses were used to identify significant associations with unfavorable biopsy conversion. The ratio [-2]proPSA/% fPSA in serum was significantly higher at diagnosis (0.87 +/- 0.44 versus 0.65 +/- 0.36 pg/mL; P = 0.02) in men developing unfavorable biopsies. [-5/-7]proPSA tissue staining was more intense (4104.09 +/- 3033.50 versus 2418.06 +/- 1606.04; P = 0.03) and comprised a greater fractional area ...Continue Reading

References

Feb 2, 1994·JAMA : the Journal of the American Medical Association·J I EpsteinC B Brendler
Nov 10, 2004·Medical Hypotheses·Michaël PeyromaureAnh Tuan Dinh-Xuan
Mar 2, 2006·Journal of the National Cancer Institute·Christopher WarlickH Ballentine Carter
Oct 16, 2007·The Journal of Urology·H Ballentine CarterJonathan I Epstein
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Aug 13, 2008·Journal of the National Cancer Institute·Anna Bill-AxelsonUNKNOWN Scandinavian Prostate Cancer Group Study Number 4
Oct 17, 2008·The New England Journal of Medicine·Yujin HoshidaTodd R Golub

❮ Previous
Next ❯

Citations

May 8, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Lori J SokollDaniel W Chan
Oct 29, 2013·TheScientificWorldJournal·Ahmet Tefekli, Murat Tunc
Jan 5, 2011·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·C R E MazzolaS F Shariat
Feb 6, 2014·Urologic Oncology·Javier Romero OteroKarim A Touijer
Apr 15, 2014·The Urologic Clinics of North America·Richard J Bryant, Hans Lilja
Aug 21, 2012·The Journal of Urology·Jeffrey J TosoianLori J Sokoll
May 12, 2015·CA: a Cancer Journal for Clinicians·Christopher P FilsonMark S Litwin
Sep 5, 2015·BioMed Research International·Jeong Hyun Kim, Sung Kyu Hong
May 27, 2011·Acta Oncologica·Shahrokh F ShariatAnders Bjartell
Mar 6, 2012·Current Opinion in Urology·Kathryn LeesChris Parker
Mar 3, 2019·Der Urologe. Ausg. A·M ChaloupkaM Apfelbeck
Dec 30, 2016·Future Science OA·Pranav SharmaJulio M Pow-Sang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.